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A b s t r a c t  
Purpose: The aim of this study was to develop and evaluate the stability of film coated Atorvastatin 
Calcium (AtC) tablets using Opadry-OY-B-28920.Method:AtC uncoated tablets were developed and 
manufactured through the Wet Granulation process. Opadry-OY-B-28920 white aqueous coating 
dispersion was used as film coating material. Results: The film coated tablets were completely 
disintegrated within 10 minutes in water media, it was also completely dissolved (more than 85% of 
the drug was released) within 30 minutes in pH 6.8buffersolutions.The film coated tablets were 
studied under both long term and accelerated stability study and the results showed no significant 
variation in physical characteristics, color, hardness, no obvious defects or signs of peeling or 
chipping. These results reflect that the film coated system Opadry-OY-B-28920 can be successfully 
used in order to produce AtC film coated tablet that is protected from environmental conditions such 
as light and humidity. Conclusion: These findings suggest that aqueous film coating with Opadry-
OY-B-28920 system is an easy and economical approach for preparing stable film coated AtC tablet 
of immediate release. 
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Introduction 
The objective of this study is to  design and develop a solid dosage 
form in a large scale manufacturing settings which will achieve 
predictable therapeutic response, and reproducible product quality. 
Realizing these objective is usually difficult and become 
challenging when the active ingredient is sensitive to environmental 
conditions. Film coating is the more contemporary and thus 
commonly used process for coating oral solid dosage forms[1] 
which will confer specific benefits that broadly range from: (i) 
improving the aesthetic qualities of the dosage form, (ii) masking 
unpleasant odor or taste and (iii) improving product stability. 
Usually film coating is obtained by spraying a thin layer of a mixture 
of film forming polymer/s, plasticizer/s and pigments on the surface 
of a solid dosage form. Selection a suitable mixture of these 
components is usually a difficult task and may result in 
unsatisfactory results in term of appearance, stability. Many 
industries of raw materials have developed a ready for use film 
coating blends, which are ready for use. These polymer blend 
formulations provide the user with the ability to impart many 
beneficial features to a solid oral dosage formulation. The most 
commonly used film coating polymers today include the cellulose 
derivatives[2]. Recently, these polymers were considered as the 
most preferred materials for producing film coating formulations in 
terms of performance and global acceptability[3, 4]. The aqueous 
based coating systems are preferred when compared with the 
organic solvent based systems as the organic solvents based 
coating systems have many drawbacks including pollution, 
explosion hazards, solvent toxicity and risks for operators[5, 6]. 
Opadry Yellow 20A82938 is an immediate release, pearlescent, 
film coating system which was to protect drug from the effect of 
moisture and light for an extended period of time without interfering 
with the immediate release profile of the drug[7, 8].It consists of a 
combination of polymers (based on hydroxypropylmethyl cellulose), 
plasticizers and pigments. The dry powder blend can be easily 
prepared by simply mixing with  water, the resulting mixture meets 
compendial requirements of the USP/EP/JPE for pharmaceutical 
applications[9]. Opadry film coating system will provide an 
excellent strength, elasticity adhesion characteristics film which 
strengthen friable cores and improve drug stability. Coatings 
prepared from such dispersions are resistant to moisture, light and 
oxidative conditions of the environment but readily dissolve at 
acidic pH. AtC is one of the most used lipid lowering agents. 
However it is a photosensitive and highly susceptible to 
degradation under acidic conditions[10]. Moreover it is available in 
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several polymorphic forms that may have different pharmacokinetic 
behaviors. Changing from polymorphic form to another may arise 
during the manufacturing process or the storage of atorvastatin 
tablets[11]. Accordingly, the used film coat should eliminate these 
inconveniences. Therefore, this study aims to develop film coated 
atorvastatin tablets using Opadry-OY-B-28920 as coating material 
and to evaluate its stability under both long and accelerated stress 
conditions, the quality of the obtained coated tablets including the 
physical appearance, hardness, weight variation and drug content 
of AtC tablets were evaluated according to the USP 33. 
Material& method 
Materials: 
Atorvastatin calcium (Arch Pharmalabs Limited), microcrystalline 
cellulose (FMC Corp, Ireland), Aerosil  (Evonik, Germany), Lactose 
Monohydrate (DMV-Fonterra, Holand), Calcium carbonate and 
magnesium stearate (Magnesia, Germany), Tween 80 (klop Ag 
Switerland) , Hydroxypropyl cellulose (SamaImpex LTD).  Sodium 
hydroxide (Merck, KgaA, and Darmstadt, Germany) dibasic sodium 
phosphate (Merck, KgaA, Darmstadt, Germany), Opadray white 
material was provided by Colorcon GmbH (Germany), Glacial 
acetic acid (Merck, KgaA, Darmstadt, Germany). Aluminum foil 
(INEOS)) and PVC (Klocknerpentaplast) and all the other 
chemicals used were of analytical grade and obtained from 
commercial sources.  
Instruments: 
The analysis and quantification of AtC in the sample was 
performed by Merck Hitachi HPLC system; (Interface module D-
7000, Autosampler L-7200, Pump L-7100, Detector L-7450) was 
used. Li Crospher 100 RP-18, 5 mm, 250´4mm was used as 
stationary phase to achieve separation. An electronic balance 
(Precisa 205 ASCS) , Thickness and diameter were measured by 
Vernier caliper (TA-100 Erweka friabilator) ,  The tablet hardness 
was tested by hardness tester (Pharma test PTB311E), ZT-
221mode disintegrator tester (Erweka, Husenstamn, Germany) 
was used to test disintegration. A dissolution apparatus (Erweka 
DT 70, Husenstamn, Germany) was used for drug release testing. 
The tablet coating was performed in a coating pan (Erweka 
GmbH., type UG, Frankfurt, Germany) using external spray gun 
and a dryer (Ceccato air compressor S.p.A, mod:8566 Mfg by CDA 
Engineering sdnBhd-Malysia). The tablets were packed using 
packing machine (Ulhmann-200, Germany). For accelerated 
stability study a stability chamber (Binder GmbH Bergster, 
Tullingen, Germany) was used. A Modulated Dynamical Scanning 
Calorimetry (MDSC Q200) made by TA instruments was used 
Methods 
Preparation of uncoated Atorvastatin (80 mg) tablets 
AtC uncoated granules were prepared by Pharmacare PLC. All the 
ingredients were properly weighed and sieved through 24 mesh. 
The granules were composed of microcrystalline cellulose, lactose 
monohydrate, sodium starch glycolate, aerosol, calcium carbonate 
and magnesium stearate. The granules were prepared by wet 
granulation method, then dried and lubricated by magnesium 
stearate. The obtained flowable granules were compressed using 
Manesty tableting machine. The average weight of the final 
uncoated tablets was about 1200 mg.  After compression,  in 
process control of AtC tablets were evaluated according to the 
USP 33 tests [17]; dissolution test  using 900ml of pH 6.8 
phosphate buffer maintained at 37°C and with the paddle II 
operating at 75 rpm was carried out according to FDA 
requirements. [18]. 
Film coating of Atorvastatin calcium (80 mg) tablet 
Preparation of Opadry Yellow 20A82938 dispersion for 
film coating 
Opadry Yellow 20A82938 (150gm) was mixed with 1000 ml 
distilled water using a mixing pan for about 20 - 25 minutes. The 
aqueous dispersion was passed though a 250 micron sieve before 
starting the coating process and was continuously stirred during 
the coating process.  
Coating methodology 
Tablet coating parameters are shown in (Table1), It was performed 
in a coating pan of 5 kg capacity using a spraying gun. The core 
tablets (4.0 kg ) were placed into the coating pan and were pre-
heated to about 40°°C by a dryer of a high pressure air spray guns. 
Warm air was then introduced into the coating pan (temperature 
55–60 °C) during the entire coating process. The spray gun was 
filled with Opadry-OY-B-28920 white aqueous dispersion and 
operated at a suitable flow rate. The motion of the pan was 
adjusted and the seal coating dispersion was sprayed onto the 
falling cores using a suitable air pressure (1.7 bars). The air heater 
was switched off and tablets blow dried for 20-25 minutes in the 
coating pan.  
The core tablets gained an extra 3% of its original weight after 
coating (Table 2). The coated tablets were then blistered in an 
aluminum-aluminum strips using (Ulhmann-200, Germany) packing 
machine.  
Evaluation of Atrovastatin Calcium (50mg) Coated 
Tablet 
Mechanical strength 
The hardness of the coated tablets was tested by randomly 
selecting 20 tablets from each three study batches at different time 
intervals of the study.  
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Disintegration test of film coated tablets 
The disintegration test of film coated Atc 80mg tablets was 
performed according to USP 33[17]. Six coated tablets of 
atorvastatin were placed in pH 6.8 buffer solutions in a USP basket 
rack assembly (Erweka ZT-2, Husenstamn, Germany) and the time 
of complete disintegration was reported.  
Assay for film coated tablets 
The percentage assay  of atorvastatin coated tablet was performed  
according to the USP 33 assay method using a reverse phase 
HPLC atλ 238nm [17]. 
Dissolution Test of Film Coated Tablets 
The dissolution test for film coated tablets was performed using a 
phosphate buffer of pH 6.8 media according to FDA 
requirements[18]. Atorvastatin release was measured in a USP 
dissolution apparatus II, the operating temperature was 37± 0.5 °C. 
The paddle stirring rate was 75 rpm. The dissolution of six tablets 
was determined after 30 minutes run; an aliquot of the fluid was 
drawn and assayed by HPLC at absorption λ of 238 nm. 
Stability study of coated tablets 
A selected samples of the film coated tablets in a blister of 
aluminum foil and PVC were subjected to both long term and 
accelerated stability study in accordance with the ICH 
guidelines[19]. The long term stability study samples kept at room 
temperature (25±2O°C) and 65±5% relative humidity conditions. 
The samples were collected for testing at a time interval of 0, 3, 6, 
9 and 12 months. The accelerated stability study were kept at 40 
°C ± 2 °C and relative humidity 75% ± 5% and were tested at time 
interval of 0, 3 and 6 months. Samples in both studies were tested 
for their appearance, disintegration, dissolution, hardness and 
assay using the above described procedures to evaluate the 
stability of the coated tablets.  
Differential Scanning Calorimetry 
The test was done to check the compatibility of the coating with the 
drug formulation; the test was performed by monitoring the thermal 
transition of the AtC and the opadry. The sample was heated from 
25 ºC to 200 ºC at ramping rate of 10 ºC/min with a nitrogen flow 
rate of 60 mL/min. 
Result and discussion 
The aim of this study was to develop film coating of atrovastatine 
calcium 80 mg tablet by using Opadry-OY-B-28920 white coating 
aqueous dispersion without a sub-coating step. Opadry-OY-B-
28920 white dispersions method consists of a simple addition of 
the formulated polymer with water. This process is efficient and 
requires little effort and time. The sieving of the dispersion was 
performed to ensure that there is no dispersed particles that could 
cause gun blockages or adversely affect the smoothness of the 
tablet film coating. The continuous stirring of the dispersion during 
the coating process was done to avoid sedimentation and 
coalescence of particles. 
The uncoated tablets were processed under strictly good condition 
in order to achieve best coating results. The granules were 
appropriately lubricated to allow good flowability in order to reduce 
tablet weight variation. The compressed granules produced tablets 
free from defects such as capping and lamination. The hardness 
(good breaking force higher than 7.0 Kps), friability (a maximum 
loss of mass not greater than 1%) physical appearance, weight 
variation and drug content evaluation of the uncoated tablets were 
found to be satisfactory. Generally tablets processed for the 
coating process must withstand the mechanical stresses and must 
have low potential for erosion or edge chipping. 
The produced coated tablets had no visible defects such as orange 
peel effect, chipping, tacking or any other physical flaws. 
Compared to the traditional aqueous film coating systems which 
consist of multiple component steps before coating; our coating 
system was dispersed in the minimum amount of time, and 
produced acceptable weight gains.  
Our tablet coating was carried out in conventional coating pan 
using spray coating technique. The temperature of coating pan and 
spray rate of coating solution were maintained properly as  
temperature in relation to the spraying rates in some studies[12, 
13] showed that at low rates; the temperature of the coating pan 
did not affect the roughness of the coated tablets while at higher 
spray rates, higher temperature gave smoother films.  
All other variables including the inlet airflow, pan speed, inlet air 
temperature, coating time, atomization pressure, and fan pressure 
were fully controlled as they significantly affect coating uniformity 
[14, 15]. Studies showed using high inlet-air temperature and low 
spray rate will slow the drug release from the coated tablets, while  
increasing the temperature in order to remove water and solvent 
from the product will affects the properties of final products[16].  
Our film coating process avoided the sub-coating step which 
sometimes is used in order to strengthen friable cores before the 
application of the coat orto prevent interaction between the drug 
substance and the coating formulation ingredients. In our study 
sub-coating was avoided to save process time, complexity, cost 
and environmental pollution due to the use of organic solvents. 
Moreover, thermal analysis was conducted to evaluate the 
compatibility between AtC and the used opadry. In this study three 
runs were done separately for the opadryl coating only, and then a 
mixture of the opadryl coating material with AtC was performed to  
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Table 1: Parameters of enteric coating process  
Factor Conditions 
Equipment Erweka Coating Pan 
Substrate  1200mg AtC Tablets 
Pan Charge  4 Kg 
Inlet Temperature 55-60 ◦C 
Bed Temperature 35-40 ◦C 
Diameter of spray tip                1.2 mm 
Distance Between spray gun  and tablet bed 15 cm 
 
 
Table 2: Parameters of film coating formulation 
Parameter Amount (% w/w) 
Theoretical weight gain 3 
Dispersion solid content 15.0 
Deionized water  72.5 
 
 
Table 3: Long term stability study of film coated Atorvastatin calcium 80 mg/tablet 
Tests Time (months) Limit 
0 3 6 9 12  
%Assay 102.5+0.3 102.3+0.1 101.7+0.1 101.9+0.5 102.2+0.2 90.0% - 110.0% 
%Dissolution  
     Average  
 Min.  (individual) 
 
100.5+2.0 
97.3+2.2 
 
100.6+3.1 
98.2+2.3 
 
100.8+1.9 
98.2+1.2 
 
101.2+1.1 
99.3+1.6 
 
100.1+2.3 
97.4+2.1 
Min. 80 
Min. 85 
Disintegration  Complete  Complete  Complete  Complete  Complete  Complete  
Appearance test Complies Complies Complies Complies Complies White tablets 
Hardness (Kb) 8.5+1.1 8.2+0.8 8.0+1.0 7.9+2.3 8.4+ 1.2 Min. 6  
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Table 4: Accelerated Stability Study of film coated Atorvastatin calcium 80 mg/tablet 
Tests Time (months) Limit 
0 3 6  
%Assay  102.5+0.3 102.6+0.3 101.1+0.5 90.0% - 110.0% 
%Dissolution  
     Min. average  
     Min. (Individual) 
 
100.5+2.0 
97.3+2.2 
 
101.3+ 1.5 
96.8+ 1.9 
 
100.9+ 1.2 
98.2+ 1.4 
Min. 80 
Min. 85 
Disintegration  Complete  Complete Complete Complete 
Appearance test Complies Complies Complies White tablets 
Hardness (Kb) 8.5+1.1 8.8+ 0.8 9.1+ 0.5 Min. 6 
 
 
 
 
 
 
 
 
Figure 2: DSC thermogram of atorvastatin Calcium and Opadray  
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Figure 3: In-vitro dissolution profile of Atorvastatin calcium 80 mg / tablet. 
 
 
 
check for its compatibility. Thermograms of pure AtC showed sharp 
endothermic peak at 156.65 °C while opadry sample showed a 
clear endothermic peak at 177.15 °C.  The same peaks were 
observed in the thermogram of the mixture of both AtC and opadry 
without any overlapping as reported in Figure 2,this clearly 
indicated there is no drug opadry interaction. 
The long term and accelerated stability study results clearly 
demonstrated that the formulated coated tablets were robust and 
all the tested parameters were constant within the studied stability 
period as reported in Table 3&4. The result in the tables clearly 
show that both the long term and accelerated study showed no 
significant variation in physical characteristics, color, hardness, no 
obvious defects or signs of peeling or chipping and the coated 
tablets showed complete disintegration and dissolution within 
sufficient time. 
In vitro drug release studies which are considered the best tool for 
assessing in vivo drug behavior were carried out and both the 
percent dissolution and assay were within the acceptable limits as 
shown in Figure 3.The figure shows no significant difference 
between the Atc film coated tablets and the reference and all were 
completely dissolved within 30 minutes 
 
Three different batches of coated atorvastatin calcium were 
prepared and tested parameters of the three batches showed no 
significant differences for each set of these batches, indicating that 
this manufacturing process is reliable and reproducible. 
Conclusion 
AtC film coated tablets were developed using Opadry-OY-B-28920 
system. Aqueous film coating was successfully conducted under 
lab-scale facilities. Opadry-OY-B-28920 system provided 
acceptable film performance. The produced coated tablets were 
stable within 12 months when stored at room temperature. 
Moreover, AtC was stable when stored for 6 months at 40 °c ± 2 
°C and relative humidity 75% ± 5%.  Three batches were produced 
and tested under the same conditions. All batches showed the 
same results which means that this formulation is reliable and 
reproducible. Therefore, these findings suggest that aqueous film 
coating with Opadry-OY-B-28920 system is an easy and 
economical approach for preparing stable atorvastatin calcium 
tablets. 
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